Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome

Clinical Nephrology

Volumn 65, Issue 6, 2006, Pages 393-400

  Westhoff, Timm H ^a   Schmidt, S ^a   Zidek, W ^a   Beige, J ^a,b   van der Giet, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Klinikum St Georg   (Germany)

Author keywords

Change disease; Focal segmental glomerulosclerosis; Minimal; Nephrotic syndrome; Steroid dependence; Steroid resistance; Tacrolimus

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENALAPRIL; FOSINOPRIL; GLUCOSE; PHENPROCOUMON; PRAVASTATIN; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; FEMALE; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY BIOPSY; MALE; NEPHROTIC SYNDROME; OPEN STUDY; PROTEIN BLOOD LEVEL; PROTEINURIA; RELAPSE; REMISSION; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREMOR;

EID: 33744960608     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp65393     Document Type: Article

References (33)

1. Bishop DK, Li W. Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. J Immunol. 1992; 148: 1049-1054.
2. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999; 56: 2220-2226.
3. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004; 15: 2169-2177.
4. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999; 353: 1083-1091.
5. Duncan N, Dhaygude A, Owen J, Cairns TD, Griffith M, McLean AG, Palmer A, Taube D. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant. 2004; 19: 3062-3067.
6. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K. Minimal-change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am J Kidney Dis. 1991; 17: 687-692.
7. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997; 30: 621-631.
8. Heering P, Braun N, Mullejans R, Ivens K, Zauner I, Funfstuck R, Keller F, Kramer BK, Schollmeyer P, Risler T, Grabensee B. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis. 2004; 43: 10-18.
9. Irish W, Sherrill B, Brennan DC, Lowell J, Schnitzler M. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation. 2003; 76: 1686-1690.
10. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis. 1994; 23: 773-783.
11. Kramer BK, Schweda F. Differing proteinuria control with cyclosporin and tacrolimus. Lancet 349: 1997; 953-954.
12. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996; 7: 56-63.
13. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004; 19: 281-287.
14. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002; 359: 741-746.
15. McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 1993; 8: 1286-1290.
16. Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis. 1991; 18: 583-588.
17. Meyrier A. Minimal-change and focal-segmental glomerular sclerosis. In: Davison AMA, Cameron S, Grunfeld JP, Ponticelli C, Von Ypersele C, Ritz E. Oxford Textbook of Clinical Nephrology. Oxford, 2005. pp 439-469.
18. Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societé de Nephrologie. Kidney Int. 1994; 45: 1446-1456.
19. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 1994; 125: 981-986.
20. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal-change nephrotic syndrome: a long-term follow-up. Kidney Int. 1986; 29: 1215-1223.
21. Patel P, Pal S, Ashley C, Sweny P, Burns A. Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal-change nephropathy, a clinical case report. Nephrol Dial Transplant. 2005; 20: 985-987.
22. Pennesi M, Gagliardo A, Minisini S. Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome. Pediatr Nephrol. 2003; 18: 477-478.
23. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993; 8: 1326-1332.
24. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993; 43: 1377-1384.
25. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995; 25: 534-542.
26. Schweda F, Liebl R, Riegger GA, Kramer BK. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant. 1997; 12: 2433-2435.
27. Segarra A, Vila J, Pou L, Majo J, Arbos A, Quiles T, Piera LL. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 2002; 17: 655-662.
28. Sonoda T, Takahara S, Takahashi K, Uchida K, Ohshima S, Toma H, Tanabe K, Yoshimura N. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. Transplantation. 2003; 75: 199-204.
29. Tang S, Tang AW, Tam MK, Ho YW. Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal-change nephrotic syndrome. Am J Kidney Dis. 2003; 42: E13-15.
30. Tejani AT, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar MR. Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int. 1988; 33: 729-734.
31. Tsugawa K, Tanaka H, Nakahata T, Ito E. Effective therapy of a child case of refractory nephrotic syndrome with tacrolimus. Tohoku J Exp Med. 2004; 204: 237-241.
32. Wang SC, Zeevi A, Jordan ML, Simmons RL, Tweardy DJ. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. Transplant Proc. 1991; 23: 2920-2922.
33. Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science. 1994; 265: 674-676.